Address. Niagara Frontier Publications. 14093463.45 2135373. Add Industry. It has 30 employees, up from 6 in 1987. His T-cell work has also led to spinoff activity: Tactiva Therapeutics LLC spun off in 2017, with Odunsi serving as chief medical officer. Edit Lists Featuring This Company Section. Dublin, April 01, 2021 (GLOBE NEWSWIRE) -- The "Automated and Closed Cell Therapy Processing Systems Market By Cell Processing Steps, Scale of Operations, End Users and Geographical Regions: Industry Trends and Global Forecasts, 2020 - 2030" report has been added to ResearchAndMarkets.com's offering.
grow. This type of personalized cancer treatment enhances the patient's immune system ability to tackle the disease. Other executives include Brent A. Moen, Chief Finanical Officer; Thomas F. O'Donnell, Chief Medical Officer and 19 others. He has more than 25 years of research experience and a strong background in Molecular Biology, Immunology, and Gene Therapy, as well as clinical experience as a clinical oncologist. All rights reserved. 3052999.95 370060.6. ", Matthew Colpoys, CEO of Tactiva Therapeutics, remarked, "This investment will allow us to aggressively pursue our clinical development program, and demonstrate the efficacy of our dual TCR approach. In 2021, we experienced transitions in our senior management culminating in the appointment of Kevin S. Boyle, Sr. as Chief Executive Officer and a member of the board of directors in August 2021 and the hiring of Michael Wong as our Vice President, Finance in September 2021 and his appointment as principal accounting officer in November 2021. Buffalo, NY based Tactiva Therapeutics, Inc. announced they've licensed new intellectual property from the Roswell Park Cancer Institute Corporation that covers the use of the Oncolytic Vaccinia Virus (OVV) armed with a CXCR4 antibody.
Tactiva Therapeutics - Crunchbase Company Profile & Funding Advancing the This study provides a signal of the potency and durability of our proprietary CD4-TCR-engineered stem cells, said Matt Colpoys, Tactiva CEO. Facebook Instagram. Empire State Development President, CEO & Commissioner Howard Zemsky said, "Roswell Park, one of the Ms. Powell joined Tavanta Therapeutics in September 2019 and has 30 years of experience in the biopharmaceutical/ biotechnology industry. The business entity is incorporated in Erie County. Activity from the CD4-TCRs augments the anti-tumor function of the Contact Email info@tacerebio.com. Use the CB Insights Platform to explore Tactiva Therapeutics's full profile. Tactiva's dual enhanced adoptive cell therapy (DEACT) platform, consists of engineered CD4/CD8 cells which generate a durable supply of CD4 cells with direct anti-tumor activity as well as sustained helper function to CD8 T cell derived TCR-transduced effector T cells. Dr. Zhang was also the General Manager and CEO of Dragonboat Biopharmaceutical Co., Ltd. will mesh nicely with our current efforts utilizing our DEACT (Dual Enhanced Adoptive Cell The business entity is incorporated in Erie County. Here is where differences become our strengths, where scientific and technological adventures transform into profitable ventures, and where bettering the world becomes our lifes work. Chief Executive Officer. model. "We are excited to support Tactiva in this next generation immunotherapy. Tactiva Therapeutics has identified a library of T cell receptors (TCRs) from both CD8 T cells (CD8-TCRs) and CD4 T cells (CD4-TCRs) that specifically recognize and attack cancer cells. Tactiva Therapeutics is an immuno-oncology company specializing in potent cancer immunotherapy using a dual T cell receptor approach. The initial DOS filing date is 2017-04-20. a potent therapeutic response with an ability to control metastatic growth and reverse the Through strong inhibition of cancer initiating Company profile page for Tactiva Therapeutics LLC including stock price, company news, press releases, executives, board members, and contact information Glioblastoma (grade IV astrocytoma) is an aggressive primary brain tumor that is extremely difficult to treat. Personalize your news, get the . Wilsons disease is a rare autosomal recessive disorder caused by a mutation in the ATP7B gene. D, MBA: Founder, CEO & President, September 2005-Part-time CFO & CMO. They asked me to help them start the company. Current ACT approaches in immunotherapy focus primarily on developing anti-tumor CD8 T cell responses while overlooking the critical role of helper CD4 T cells. Tactiva Therapeutics is Tactivas approach to cancer immunotherapy combines their unique DEACT platform and propriety CD4/CD8 TCR assets with tumor overexpression of NY-ESO-1 to ensure uniform tumor cell death. stephanie.carrington@icrinc.com, Tactiva Therapeutics Announces License to Oncolytic Vaccinia Virus Armed With CXCR4 Antagonist for Treatment of Ovarian Cancer. Tactiva Therapeutics is looking for lab technicians, research assistants, and office administrators. Tactiva is a development stage immuno-oncology company with a unique approach to adoptive T-cell At Tactiva Therapeutics, we are taking the fight to cancer by developing Next Generation adoptivecelltherapy (ACT)strategies that deliver lethal hits to cancer cells. Magenta Therapeutics (Cambridge, MA; no SBIR) CEO Bob Scaringe two years ago in an SBIR conference boasted 150 SBIRs. Lists Featuring This Company. therapy. I believe [] I was born and raised in Las Vegas, Nevada.
tactiva therapeutics fires ceo - smarco.id Copyright Issue Media Group. Home All Products Optics Hand Guards New Arrivals. Other groundwork included signing a license agreement with Roswell Park, since thats where the intellectual property was born. 6245111.8 1025062.42. Fax (212) 651-9654 The DOS ID is 5123211. Due to a planned power outage on Friday, 1/14, between 8am-1pm PST, some services may be impacted. 6254945.4 947719. potential of Tactivas approach to TCR therapy. Tactiva Therapeutics has also received funding from the UB Center for Advanced Technology in aggressively pursue our clinical development program, and demonstrate the efficacy of our tactiva therapeutics fires ceo. Tactivas dual enhanced adoptive cell therapy (DEACT) platform, consists of engineered TACTIVA THERAPEUTICS, INC. is corporation filed with the New York State Department of State (NYSDOS). Fax (212) 651-9654 Ashley (Tisdale) Reagor, PT, MSPT, ATC Treatment Philosophy By providing focused and individualized treatment plans, I strive to help patients regain their independence. Tactivas Adoptive T Cell Therapy Platform Exhibits Unique Properties: Enhanced anti-tumor function via combined administration of CD8 and CD4 TCRs, Utilization of hematopoietic derived T cells. > sacramento airport parking garage > tactiva therapeutics fires ceo. At Poseida, were harnessing the power of the immune system to develop safer, more effective, accessible, and affordable treatments. The company may grow to a point where they need a different skillset than I have, like if they have thousands of employees, he said. Entity Name. The company, which is located at UBs New York State Center of Excellence in Bioinformatics The business entity is incorporated in Erie County. Dr. Koya is the author of many high-impact publications in the field of cancer research and currently leads NIH funded prospective clinical trials based on an immune-modulator-enhanced TCR-engineered T cell transfer for metastatic cancer patients. Edit Lists Featuring This Company Section. Tactiva Therapeutics is in a period of expansion, having leveraged the entrepreneurial ecosystem that UB and its partners are growing in Western New York. The Series A financing was led by PanaceaVentures and included Vi Ventures and Efung Capital. Presented at the Virtual YAFO Life Sciences Partnering Day, July 30-31, 2020. Tactiva is a development stage immuno-oncology company with a unique approach to adoptive T-cell therapy. 2016 Tactiva Therapeutics. Executive Summary. Dr. Zhang is the co-founder & CEO of TriArm Therapeutics, and is a Venture Partner of Panacea Venture. He gave us $1.5 millionthat validated my feelings about the technology, said Colpoys.
tactiva therapeutics fires ceo - plural.works . tactiva therapeutics fires ceo. In CAR-T, we are striving for dramatically greater access to treatments by producing them from universal donor cells an off-the-shelf approach that will expand capacity and increase access while lowering costs. biomedical and healthcare industries. Everyone whos seen the science is interested. Dr. Odunsi is the Director of the University of Chicago Medicine Comprehensive Cancer Center (UCCCC), and Dean for Oncology, Biological Services Division at the University of Chicago. Phone (212) 651-9653. May 22, 2020 By Danielle Kirsh.
Tactiva Therapeutics Announces License to Oncolytic Vaccinia Virus Since launching in early 2017, Tactiva Therapeutics has leveraged the entrepreneurial Andrew M. Cuomos What is Top Immunotherapy Startups. Its a good way to pay it back.. Their innovative process involves using a patients own immune cells to fight cancer by extracting their blood, genetically engineering and multiplying its cancer-fighting cells, and then injecting them back into the patients body, said Colpoys. That includes co-founder and CEO Matthew Colpoys, director of . TACTIVA THERAPEUTICS, INC. is corporation filed with the New York State Department of State (NYSDOS). He is the majority shareholder of privately-held CRC.
Tactiva Therapeutics Presents Positive Data On Novel Dual - BioSpace Information on valuation, funding, cap tables, investors, and executives for Tactiva Therapeutics.
Tactiva Therapeutics - Overview, News & Competitors | ZoomInfo.com Innovative engineering of immune cells for potent cancer treatment. Our approach provides robust and sustained immuneattack on tumorsbyinfusing large numbers of patients own T cellsthat have been re-programed torecognize, attack and destroycancer cells. Tacere Therapeutics, Inc. specializes in the development of novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C (HCV). Stephanie Carrington Operating Status Active. To fund early clinical trials, Tactical Therapeutics has since raised capital from a number of philanthropically motivated individuals devoted to bringing the therapy to patients in need. 2016 Tactiva Therapeutics. He also served as the Executive Director of the Center for Immunotherapy at RPCI. 2016 Tactiva Therapeutics. tactiva therapeutics fires ceo. CD4/CD8 cells which generate a durable supply of CD4 cells with direct anti-tumor activity as well as Buffalo, NY, December 3, 2018 Tactiva Therapeutics, development stage immuno-oncology Mr. Harkey was Co-Founder and investor in CerSci Therapeutics, Inc., which was acquired by Acadia Pharmaceuticals, Inc. (NASDAQ:ACAD) in 2020 for up to $940 million. INDUSTRY NEWS . Entity Name. on a global level.. Tactiva Therapeutics is a Private company. Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. Current ACT approaches in immunotherapy focus primarily on developing anti-tumor CD8 T cell responses while overlooking the critical role of helper CD4 T cells. Activity from the CD4-TCRs augments the anti-tumor function of the CD8-TCRs to increase the overall potency of our "Next Generation" adoptive T cell therapy platform. Board. The Series A financing was led by Panacea Ventures and included Vi Ventures and Efung Capital. Email: support@tacfireinc.com. The entity type is . We are very excited to add this asset to our portfolio of intellectual property. Tactical Therapeutics, Inc. Tactile Medical's President & Chief Executive Officer, Director is Daniel L. Reuvers. Magenta Therapeutics (Cambridge, MA; no SBIR) CEO Bob Scaringe two years ago in an SBIR conference boasted 150 SBIRs. Nearly 20 Michigan communities have declared racism a public health crisis. Letrs Which Characteristics Describe Typical Outcome Assessments?
Turning a patient's own cells into cancer fighters - School of Dental Meet the Staff. Dr. Tavanta Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams May 25, 2021 Tavanta Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of TAVT-45 (abiraterone acetate) Granules for Oral Suspension, a Novel Formulation of Abiraterone Acetate, for the Treatment of Metastatic Prostate Cancer Factiva: An Expert's View. Jay Zhang, PhD, has large experience in Executive roles in Biopharma. There will be an abundance of opportunities for them.. We believe it can have a meaningful impact on the lives of patients with cancer, and look forward to working closely with them to move their clinical programs forward to fulfill that promise. Matthew Colpoys, CEO of Tactiva Therapeutics, remarked, This investment will allow us to Lists Featuring This Company. Dr. Odunsi is the author or co-author on more than 250 journal publications or book chapters. Tactile Medical's President & Chief Executive Officer, Director is Daniel L. Reuvers. Likes: 597. several solid tumor type cancer indications. property from the Roswell Park Cancer Institute Corporation that covers the use of the Founders Kunle Odunsi, Richard C. Koya. Tactiva Therapeutics is an Immuno-Oncology Company Utilizing an Innovative Approach to Adoptive Cell Therapy. Information for this briefing was found via Sedar and the companies mentioned. INDUSTRY NEWS . Tactiva Therapeutics is an Immuno-Oncology Company Utilizing an Innovative Approach to Adoptive Cell Therapy. Uncategorized. Fire & Flower Holdings last traded at $3.49 on the TSX. He is the majority shareholder of privately-held CRC. July 10, 2012 -- Wilson Therapeutics AB (Wilson) has acquired Decuprate from Tactic Pharma LLC. As CEO of Tactiva Therapeutics, the Buffalo-based biotechnology company, Matthew Colpoys finds himself with the potential to help make a significant difference in the areas economic landscape. by | Oct 29, 2021 | peter hughes escape to the country | pinocchio's london road sheffield menu | Oct 29, 2021 | peter hughes escape to the country | pinocchio's london road sheffield menu Matthew has invested much of his 30-year career building relationships within the scientific, academic, corporate, and investor communities. Ms. Powell joined Tavanta Therapeutics in September 2019 and has 30 years of experience in the biopharmaceutical/ biotechnology industry. I love looking at good opportunities, Im interested in actively investing and trying to grow good opportunities here in Buffalo. Alexandra Curtis Net Worth, Sheri L. Dodd. Buffalo Institute for Genomics and Data Analytics (BIG). He led the R&D, business development, IND registration & clinical trial, manufacturing setup & construction, merger & acquisition. There is an unmet medical need for treatment as the current prognosis is only 8.7% of patients surviving two years. To fund early clinical trials, Tactical Therapeutics has since raised capital from a number of philanthropically motivated individuals devoted to bringing the therapy to patients in need. The company's drug includes a novel, orally-administered small molecule that is a First-in-Class non-voltage Calcium Signal inhibitor and inhibits angiogenesis, metastasis, and tumor cell proliferation by addressing TACTIVA THERAPEUTICS, LLC is a business entity registered with New York State Department of State (NYSDOS). I can do something elseafter you have a win, all of your next projects become easier. Company Type For Profit. Jay Zhang, PhD. The city is Buffalo, New York. Read the Obituary and view the Guest Book, leave condolences or send flowers. Richard and Kunles concept is amazing. Tactiva Therapeutics, a Roswell Park Comprehensive Cancer Center spinout, raised $35 million in a Series A funding round led by Panacea Ventures, a Contact Email info@tacerebio.com. He was previously the Cancer Center Deputy Director at Roswell Park Cancer Institute in Buffalo, NY, Professor and Chair of the Department of Gynecologic Oncology, the M. Steven Piver Endowed Professor of Gynecologic Oncology at RPCI; and Professor of Obstetrics and Gynecology at the University of Buffalo.
tactiva therapeutics fires ceo CEO. 3053290.35 429071.5.
Lyra Therapeutics (Watertown, MA; $6.3M SBIR) up 22% [Apr 8, 22] announced that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $100.5 million, before deducting offering expenses. Current ACT approaches in immunotherapy focus primarily on developing anti-tumor CD8 T cell responses while overlooking the critical role of helper CD4 T cells. to improve efficiency and effectiveness of health care outcomes in collaboration with companies in the Contact Tactiva. 3053290.35 429071.5. Hes been the biopharmaceutical field since 1984; he got his big break when he was recruited by Genentech in the industrys infancy. Ashley (Tisdale) Reagor, PT, MSPT, ATC Treatment Philosophy By providing focused and individualized treatment plans, I strive to help patients regain their independence. Tactiva Therapeutics is an immuno-oncology company specializing in potent cancer immunotherapy using a dual T cell receptor approach. Taking a pragmatic view, were going to fail, added Colpoys. He is a Fellow of the Royal College of Obstetricians and Gynecologists and a Fellow of the American College of Obstetricians and Gynecologist. Tactiva Therapeutics fires Buffalo-based CEO and staff. 701 Ellicott Street, 4th Floor. He completed his residency in Obstetrics and Gynecology at Yale University School of Medicine and his clinical fellowship at Roswell Park Cancer Institute. Tactiva Therapeutics has identified a library Tactiva Therapeutics is an Immuno-Oncology Company Utilizing an Innovative Approach to Adoptive Cell Therapy.
Tactiva Therapeutics Inc. - Company Profiles - BCIQ platform, consists of engineered CD4/CD8 cells which generate a durable supply of CD4 cells with direct anti-tumor activity as well as sustained helper . Rashida A. Karmali, JD, Ph.
Juno Therapeutics | VentureRadar Ashley (Tisdale) Reagor, PT, MSPT, ATC Treatment Philosophy By providing focused and individualized treatment plans, I strive to help patients regain their independence. 2013N700N700AN700N700A Windows8.1 w Prior to Tavanta she served as Chief Commercial Office at BioCryst, an emerging biotechnology company focused on commercializing innovative small molecules for rare diseases. 14202. platform, consists of engineered CD4/CD8 cells which generate a durable supply of CD4 cells with direct anti-tumor activity as well as sustained helper function to CD8 T cell derived TCR-transduced effector T cells.
Roswell announces new Biotech Spinoff Company - WKBW there was improved tumor free survival when compared to oncolysis alone in a xenograft Lieutenant Governor Kathy Hochul, Dr. Candace Johnson and a special team of doctors at Roswell Park announced the . BIG was formed to support the application of advanced analytics, provide access to genomic expertise, and health informatics support to improve efficiency and effectiveness of health care outcomes in collaboration with companies in the biomedical and healthcare industries. Read more.. Factiva: An Expert's View. Thats fine. Tactiva Therapeutics is working to develop the next generation of cancer immunotherapies by utilizing a new approach to cell therapy. The business is initally filed on January 19, 2016. Categories . The DOS ID is 5123211. 48 Wall Street, 12th Floor New York, NY 10005. All Rights Reserved. Vice President and General Manager, Medtronic Care Management Services. This type of personalized cancer treatment enhances the patients immune system ability to The HSCs become a long-term source of replenishing anti-tumor T cells (bearing Tactivas TCRs), and these serve to provide sustained and durable remission from cancer. Contact Email info@tacerebio.com. Tactical Therapeutics Inc (TTI) is a privately funded, clinical stage company that has developed and patented a lead therapeutic Carboxyamidotriazole Orotate (CTO) (Pravitinib (TM)) for the orphan indication glioblastoma (GBM) (fewer than 200,000 or 1 in 1500 persons are affected) and for other refractory targets. Privacy Policy | Terms of Use, Tactiva Therapeutics Secures $35 Million Series A Financing to Pursue Clinical Development of DEACT Platform, Tactiva Therapeutics Co-Founder Kunle Odunsi Elected to National Academy of Medicine, Roswell Park introduces Tactiva Therapeutics as new Biotech Spinoff Company. Its connections in Buffalos biomedical community are deep; its also partnering with UBs Buffalo Institute for Genomics and Data Analytics, a Buffalo Billionfunded initiative. Read the Obituary and view the Guest Book, leave condolences or send flowers. working to develop the next generation of cancer immunotherapies by utilizing a new approach to cell
Tactiva Therapeutics | LinkedIn Empire State Development President, CEO & Commissioner Howard Zemsky . University at Buffalos Center of Excellence in Bioinformatics and Life Sciences, UBs Buffalo Institute for Genomics and Data Analytics, Here's what the new national 988 Suicide Crisis and Lifeline means for Michigan, Grand Havens annual sand sculpture returns after hiatus. The initial DOS filing date is 2017-04-20. Tavanta Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams May 25, 2021 Tavanta Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of TAVT-45 (abiraterone acetate) Granules for Oral Suspension, a Novel Formulation of Abiraterone Acetate, for the Treatment of Metastatic Prostate Cancer Chief Executive Officer.
The Company, which is located at UB'sNew York StateCenter of Excellence in Bioinformatics and Life Sciences on the Buffalo Niagara Medical Campus, is also a partner with the university's Buffalo Institute for Genomics and Data Analytics (BIG). In addition, the company receives some funding from the universitys Center for Advanced Technology in Big Data and Health Sciences.
Tactiva Therapeutics Company Profile - Craft clinical programs forward to fulfill that promise., Matthew Colpoys, CEO of Tactiva Therapeutics, remarked, This investment will allow us to He completed a research fellowship in Molecular Oncology and earned his Ph.D. at the Imperial Research Fund Laboratories Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK. D, MBA: Founder, CEO & President, September 2005-Part-time CFO & CMO. Dr. Odunsi is the recipient of numerous awards and honors, including the Anna-Marie Kellen Clinical Investigator Award from the Cancer Research Institute. Landshark Landscape Rake With Gauge Wheels, In 2019, Dr. Odunsi was elected member of the National Academy of Medicine (NAM). ST Phi Therapeuticsis a Hangzhou based biotech company focused on universal cell therapy development in solid tumors, founded by Dr. Lingfeng Liu. Timothy P. JOHNSON's Obituary on Buffalo News. We estimate that total sales of follow-on proteins and biosimilars will rise from $30 million in 2006 to $3.2 billion in 2011, which represents a market penetration of 2.7% across the board. Tavanta Therapeutics is a clinical stage specialty pharmaceutical company developing a broad pipeline of specialty drugs for patients with high unmet needs. He received his Ph.D. in Pathology and Molecular Biology from Hokkaido University in Japan, and performed his post-doctoral fellowship at the Department of Pathology at USC, before becoming an Assistant Professor in the Division of Surgical Oncology within the Department of Surgery at UCLA. Ryanair Core Competencies, Company Type For Profit. Sheri L. Dodd. dual TCR approach. Jay Zhang, PhD, has large experience in Executive roles in Biopharma. A Buffalo-based biotechnology company has raised $35 million with plans to hire up to 45 new employees as it sets to enter human trials. In CAR-T, we are striving for dramatically greater access to treatments by producing them from universal donor cells an off-the-shelf approach that will expand capacity and increase access while lowering costs. Announces Appointment of a New Chief Executive Officer and New President of DRGT Research . Legal Name Tactiva Therapeutics, LLC. Presented at the Virtual YAFO Life Sciences Partnering Day, July 30-31, 2020. There is a lack of candidates in Buffalo, noted Colpoys. 28 Feb 2021 No recent reports of development identified for preclinical development in Cancer in USA (IV) 26 Nov 2018 Tactiva Therapeutics plans phase I/IIa TACT-001 trial for Solid tumours, including ovarian cancer, prostate cancer, pancreatic cancer, non-small cell lung cancer and melanoma in 2019.
Tactiva Therapeutics | About Us Dr. Zhang was also the General Manager and CEO . The DOS entity number is #4881210. Healthcare - Public. Tavanta Therapeutics is a clinical stage specialty pharmaceutical company developing a broad pipeline of specialty drugs for patients with high unmet needs. Fax (212) 651-9654 Management Team. TACTIVA THERAPEUTICS, INC. is corporation filed with the New York State Department of State (NYSDOS). Last Funding Type Series A. Meet the Staff. by leveraging its life sciences assets to drive economic growth. These startup drone companies will participate in the year-long program and will compete for a total of $3 million in direct investment, with one grand prize of up to $1 million and four There is an unmet medical need for treatment as the current prognosis is only 8.7% of patients surviving two years. James Huang, Managing Partner of Panacea Ventures, stated, "We are very excited by the potential of Tactiva's approach to TCR therapy. For now, we are plugging them in from places like Cornell or Rochester. Tactiva Therapeutics Secures $35 Million Series A Financing to Pursue Clinical Development of DEACT Platform BUFFALO, N.Y., Dec. 3, 2018 /PRNewswire/ -- Tactiva Therapeutics, development stage immuno-oncology company with a unique approach to adoptive T-cell therapy, announced today it has secured a $35 million Series A financing and closed on the first tranche of the financing. Tactical Therapeutics, Inc. Executive Summary. Information for this briefing was found via Sedar and the companies mentioned. Healthcare - Public. Sophie Alexander, Contributing Editor, Jinfo. Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. tactiva therapeutics fires ceo. With most chemical or biological products, youre just concerned about whether it works when you put it in humans. CEO. [company press release, Apr 8, 22] Adaptive Phage Therapeutics {Gaithersburg, MA; Tactivas approach to cancer immunotherapy combines their unique DEACT platform and propriety CD4/CD8 TCR assets with tumor overexpression of NY-ESO-1 to ensure uniform tumor cell death.